Cardinal Health, Inc. (CLH.F)
| Previous close | 90.26 |
| Open | 90.62 |
| Bid | 91.70 x 20000 |
| Ask | 91.98 x 20000 |
| Day's range | 90.62 - 90.62 |
| 52-week range | 75.52 - 106.30 |
| Volume | |
| Avg. volume | 34 |
| Market cap | 22.314B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 43.15 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.88 (2.08%) |
| Ex-dividend date | 01 July 2024 |
| 1y target est | N/A |
- PR Newswire
Cardinal Health Board of Directors Approves Increase to Quarterly Dividend
Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the close of business on July 1, 2024.
- PR Newswire
Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance
Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were $1.05, which included a non-cash, pre-tax goodwill impairment of $90 million related to the Global Medical Products and Distribution (GMPD) segment as a result of the reallocation of goodwill related to the reporting structure update.
- PR Newswire
Cardinal Health Reaffirms Fiscal 2024 non-GAAP EPS Guidance and Long-term Targets Amidst Nonrenewal of OptumRx Customer Contracts
Cardinal Health (NYSE: CAH) announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35. Despite the nonrenewal of the OptumRx contracts, the company also reiterated both its Pharmaceutical and Specialty Solutions long-term segment profit CAGR target of 4% to 6% and its consolidated non-GAAP EPS CAGR target of 12% to 14% for fiscal yea
